SO WHAT: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is ...

Viatris Inc. closed 33.95% short of its 52-week high of $13.55, which the company achieved on November 25th.

NEW YORK, NY / ACCESS Newswire / March 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc.

Viatris Inc. closed 31.37% below its 52-week high of $13.55, which the company reached on November 25th.

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

New York, New York--(Newsfile Corp. - March 21, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pliant Therapeutics, Inc. ("Pliant" or ...

This leaflet answers some common questions about COSAMIDE 50. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines ...

After hours: March 25 at 7:59:40 PM EDT Loading Chart for VTRS ...

One company that received approval for an insulin biosimilar in the US is Viatris, for its Semglee (insulin glargine-yfgn) product. In a recent fourth quarter investor call, Sanjeev Narula ...